Status:
COMPLETED
A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
Lead Sponsor:
Eisai Inc.
Conditions:
Partial Onset Seizures
Eligibility:
All Genders
18+ years
Brief Summary
This was a Non-interventional Prospective Study. Centres enrolled adult patients with partial-onset seizures with or without secondary generalisation for whom the clinician had decided to initiate Esl...
Eligibility Criteria
Inclusion
- The decision to prescribe ESL was made by the physician before and independently of his/her decision to include the patient in the study
- Patients treated with one drug licensed for monotherapy in partial onset seizures
- Based on the physician's clinical judgment, the patient seizure activity was not controlled sufficiently with a current monotherapy and it was in the patient's best interest to be prescribed adjunctive ESL
- Patient was prescribed ESL no longer than 2 weeks before the baseline
- Treatment with ESL was to be commenced in line with the drug's license and Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC)
- Aged 18 years or older
- Signed written informed consent
Exclusion
- Patients that had started ESL outside the approved SPC at enrolment
- Simultaneous participation in an interventional clinical trial
Key Trial Info
Start Date :
April 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
254 Patients enrolled
Trial Details
Trial ID
NCT01830400
Start Date
April 1 2012
End Date
June 1 2014
Last Update
August 19 2015
Active Locations (106)
Enter a location and click search to find clinical trials sorted by distance.
1
Hradec Králové, Czechia
2
Kroměříž, Czechia
3
Prague, Czechia
4
Aalborg, Denmark